|
Available clinical and mutational data on affected patients and gene carriers of PDB |
||||
| Pedigree number (sex) |
Age at clinical diagnosis or DNA evaluation; present age (years) |
AP (U/l) |
PDB-related clinical finding |
Other relevant clinical data |
|
|
||||
| II-3 (M)a |
Deceased |
Unknown |
Diffuse marked bone deformities (Fig. 2a) |
Died at age 76 years from Alzheimer's disease |
| II-8 (F)a |
Deceased |
Unknown |
Bone deformities at both lower extremities |
Died at age 52 years from colon-rectal cancer; also had breast cancer |
| II-10 (F)a |
Deceased |
Unknown |
Multiple marked diffuse skeletal deformities |
Died at age 92 years from unknown cause |
| III-1 (F)b |
57; 65 |
357 |
Third lumbar vertebra, pelvis, right proximal femur |
Alive |
| III-3 (F)b |
53; 79 |
560 |
Pelvis, both tibias |
Alive. Apparently healthy |
| III-5 (M)a |
Not assessed |
Unknown |
Diffuse bone pain |
Died at age 80 years from unknown cause |
| III-6 (F)a |
62; deceased |
2,259 |
Right pelvis and proximal femur, IV and VIII left ribs |
Died 12 years previously from osteogenic sarcoma on Pagetic bone (right pelvis) |
| III-12 (M)b |
64; 82 |
380 |
Left hipc |
Alive. Benign prostate hyperplasia |
| III-13 (M)b |
65; 83 |
610 |
T5, T10 and L4 vertebral bodies, sacrum, right tibia, right femur, right shoulder and collarbone |
Alive. Allergy to pollen, hypertensive cardiopathy |
| IV-1 (F) |
41 |
<120 |
None |
Alive, age 42, healthy |
| IV-13 (F) |
53 |
<120 |
None |
Alive, hypertension, age 54 |
| IV-14 (F) |
41 |
<120 |
None |
Alive, age 42, lumbar–sacral discal hernia, goitre |
| IV-15 (M) |
47 |
<120 |
None |
Alive, age 48 allergy to pollen |
| IV-16 (F) |
48 |
<120 |
None |
Alive, age 49, allergy to pollen |
|
The M404V mutation was ascertained in individuals listed in bold. The highest observed levels of alkaline phosphatase (AP) are reported for each affected subject; the normal range is less than 120 units/l. PDB, Paget's disease of bone. aIndividuals strongly suspected to be potential PDB patients after careful reconstruction of the familial clinical history. bThese subjects received two treatment courses with oral risedronate (30 mg/day) for 3 months followed by a 112-day follow-up period without treatment [24]; complete normalization of serum AP levels and bone pain remission were observed in all these treated subjects. cTotal bone scintigraphy was not performed on this subject; the skeletal extent of PDB is on the basis of X-ray evaluations. | ||||
Falchetti et al. Arthritis Research & Therapy 2005 7:R1289 doi:10.1186/ar1828 |
||||